Peptide Schedule
Triptorelin10 residuesQHWSYGLRPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Triptorelin Dosage Calculator

Sexual HealthInjectionFDA Approved~3-8 hours half-life

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), with a D-tryptophan substitution at position 6 that makes it resistant to enzymatic degradation.

Single 100mcg dose can trigger an acute LH/FSH surge to restart natural testosteroneFDA-approved compound with decades of clinical safety data (Trelstar)May restore HPTA function after prolonged anabolic steroid-induced suppressionWorks directly on pituitary GnRH receptors — no need for intact hypothalamic signaling

100mcg · Single dose

100500
100.0 units
100 units (1mL)
Concentration
100
mcg/mL
Draw Volume
1.000
mL
Syringe Units
100.0
units
Doses / Vial
1
doses

Summary: Add 1mL BAC water to your 0.1mg vial. Draw to 100.0 units on a U-100 syringe for a 100mcg dose. This vial will last 1 doses.

Cycle Planner

Subcutaneous or Intramuscular. Typical beginner frequency: single dose.

Triptorelin Pharmacokinetics

Triptorelin Dosing Protocol

LevelDose / InjectionFrequency
Beginner100mcgSingle dose
Moderate100mcgSingle dose
Aggressive100mcgSingle dose

Note: IMPORTANT: In PCT context, triptorelin is used as a ONE-TIME 100mcg injection — not repeated dosing. A single low dose triggers an acute LH/FSH surge that can restart testosterone production. Do NOT repeat the dose. Repeated or high-dose administration causes the opposite effect: pituitary downregulation and chemical castration. This is the same compound sold as Trelstar for prostate cancer, but at 37,500x the PCT dose.

About Triptorelin

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), with a D-tryptophan substitution at position 6 that makes it resistant to enzymatic degradation. It is FDA-approved under the brand name Trelstar for the palliative treatment of advanced prostate cancer, and also used clinically for endometriosis, uterine fibroids, central precocious puberty, and gender-affirming hormone therapy. The defining feature of triptorelin is its dose-dependent paradox. A single low dose (100mcg SC/IM) produces an acute flare — a rapid surge in LH and FSH from the pituitary — which stimulates the testes to produce testosterone. This is the basis of its off-label use in post-cycle therapy (PCT) after anabolic steroid cycles. A landmark case report by Pirola et al. (2010) documented a bodybuilder with 13 years of steroid-induced hypogonadism whose testosterone normalized within one month after a single 100mcg triptorelin injection. In contrast, continuous or depot administration (3.75mg monthly, 11.25mg quarterly, or 22.5mg semi-annually) causes sustained GnRH receptor stimulation. After an initial 1-2 week flare, the pituitary GnRHR receptors internalize and downregulate, shutting off LH/FSH production entirely. Testosterone drops to castrate levels — which is the therapeutic goal in prostate cancer. The same molecule that restarts hormone production at 100mcg will permanently suppress it at milligram doses. This is why triptorelin must never be dosed repeatedly in a PCT context.

Frequently Asked Questions